A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to study entry * Karnofsky Performance Status of \>/= 70 at screening * Confirmed measurable disease per RANO * Adequate hematologic and organ function Patients enrolled in Stage 1: * Histologically documented recurrent or progressive high-grade gliomas (WHO Grade III-IV) * Prior treatment with at least one regimen for gliomas (radiotherapy with or without chemotherapy for Grade III gliomas and radiotherapy with chemotherapy for Grade IV gliomas) and/or not considered to be a candidate for regimens known to provide clinical benefit Patients enrolled in Stage 2: * Histologically documented recurrent or progressive glioblastoma (WHO Grade IV gliomas) * Prior treatment with one or two regimens for glioblastoma (with the initial regimen consisting of radiotherapy with chemotherapy) Exclusion Criteria: * Treatment with anti-tumor therapy (approved or experimental) within 4 weeks prior to initiation of study drug * Requirement for anticoagulants such as warfarin or any other warfarin-derivative anticoagulants; low-molecular-weight heparin is permitted * Any contraindication to MRI examination * Evidence of Grade \>/= 1 intracranial hemorrhage * Active congestive heart failure or ventricular arrhythmia requiring medication * Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse or cirrhosis * Unresolved toxicity from prior therapy with the exception of lymphopenia (for patients with prior temozolomide) and alopecia * Pregnant or lactating women